A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.
Also called NCT02584660
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 114 participants
- Registry
-
NCT02584660
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02584660. Randomized; no masking; primary purpose treatment. Start 2015-10-15 (actual); primary completion 2017-03-22 (actual). Results posted on 2018-04-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
- Acronym
- MERCURY PE
- Condition
- Pulmonary Embolism
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Standard-of-care
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02584660- Content hash
4f645c75572699b776d466ba9529a5cebe70730199c4df7a9091bd55ec5789da